Skip to main content
×
×
Home

Maintaining high rates of measles immunization in Africa

  • J. LESSLER (a1), W. J. MOSS (a1), S. A. LOWTHER (a1) and D. A. T. CUMMINGS (a1)
Summary

Supplementary immunization activities (SIAs) are important in achieving high levels of population immunity to measles virus. Using data from a 2006 survey of measles vaccination in Lusaka, Zambia, we developed a model to predict measles immunity following routine vaccination and SIAs, and absent natural infection. Projected population immunity was compared between the current programme and alternatives, including supplementing routine vaccination with a second dose, or SIAs at 1-, 2-, 3-, 4- and 5-year intervals. Current routine vaccination plus frequent SIAs could maintain high levels of population immunity in children aged <5 years, even if each frequent SIA has low coverage (e.g. ⩾72% for bi-annual 60% coverage SIAs vs. ⩾69% for quadrennial 95% coverage SIAs). A second dose at 12 months with current coverage could achieve 81% immunity. Circulating measles virus will only increase population immunity. Public health officials should consider frequent SIAs when resources for a two-dose strategy are unavailable.

Copyright
Corresponding author
*Author for correspondence: Dr J. Lessler, Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, 615 N. Wolfe St, Baltimore, MD 21224, USA. (Email: jlessler@jhsph.edu)
References
Hide All
1.World Health Organization, United Nations Children's Fund. Measles mortality reduction and regional elimination strategic plan 2001–2005. Geneva: WHO, 2001.
2.Centers for Disease Prevention and Control. Progress in global measles control and mortality reduction, 2000–2006. Morbidity and Mortality Weekly Report 2007; 56: 12371241.
3.World Health Organization, United Nations Children's Fund. GIVS: Global Immunization Vision and Strategy 2006–2015. Geneva: WHO, 2005.
4.Orenstein, WA, et al. Measles eradication: is it in our future? American Journal of Public Health 2000; 90: 15211525.
5.World Health Organization. World Health Organization Regional Office for Africa Measles SIAs Field Guide. Geneva: WHO, 2006.
6.Agur, Z, et al. Pulse mass measles vaccination across age cohorts. Proceedings of the National Academy of Sciences USA 1993; 90: 1169811702.
7.Shulgin, B, Stone, L, Agur, Z. Pulse vaccination strategy in the SIR epidemic model. Bulletin of Mathematical Biology 1998; 60: 11231148.
8.Nokes, DJ, Swinton, J. The control of childhood viral infections by pulse vaccination. IMA Journal of Mathematics Applied in Medicine and Biology 1995; 12: 2953.
9.WHO. Measles vaccines: WHO position paper. Weekly Epidemiological Record 2009; 84: 349360.
10.Pan, C et al. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus monkeys from measles. Journal of Virology 2010; 84: 37983807.
11.Griffin, D, Pan, C, Moss, WJ. Measles vaccines. Frontiers in Bioscience 2008; 13: 13521370.
12.Hethcote, HW. The mathematics of infectious diseases. SIAM Review 2000; 42: 599653.
13.Anderson, RM, May, RM. Infectious Diseases of Humans: Dynamics and Control. Oxford; New York: Oxford University Press, 1991.
14.Grais, RF, et al. Estimating transmission intensity for a measles epidemic in Niamey, Niger: lessons for intervention. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006; 100: 867873.
15.Scott, S, et al. Estimating the force of measles virus infection from hospitalised cases in Lusaka, Zambia. Vaccine 2004; 23: 732738.
16.World Health Organization. Progress in measles control: Zambia, 1999–2004. Weekly Epidemiological Record 2005; 24: 213220.
17.Lowther, SA, et al. Population immunity to measles virus and the effect of HIV-1 infection after a mass measles vaccination campaign in Lusaka, Zambia: a cross-sectional survey. Lancet 2009; 373: 10251032.
18.Venables, WN, Ripley, BD. Modern Applied Statistics with S-PLUS, 3rd edn. New York: Springer, 1999.
19.Caceres, VM, Strebel, PM, Sutter, RW. Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clinical Infectious Diseases 2000; 31: 110119.
20.Gans, HA, et al. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. Journal of the American Medical Association 1998; 280: 527532.
21.Government of the Republic of Zambia. Zambia Demographic and Health Survey 2001–2002. Central Statistical Office (Zambia) CBHZORCM, ed. Lusaka and Maryland: Central Board of Health and ORC Macro, 2003.
22.U.S. Census Bureau. U.S. Census Bureau International Database (IDB) (http://www.census.gov/ipc/www/idb/worldpop.html). Accessed 1 June 2008.
23.Duda, RO, Hart, PE, Stork, DG. Pattern Classification, 2nd edn. New York: Wiley, 2001.
24.Ohuma, EO, et al. Evaluation of a measles vaccine campaign by oral-fluid surveys in a rural Kenyan district: interpretation of antibody prevalence data using mixture models. Epidemiology and Infection 2009; 137: 227233.
25.Wood, JG, et al. Potential impacts of schedule changes, waning immunity and vaccine uptake on measles elimination in Australia. Vaccine 2009; 27: 313318.
26.World Health Organization. Report of the Second Measles Technical Advisory Group Meeting. Addis Ababa, 8–9 May 2008 (http://www.afro.who.int/measles/2ndtagmeeting/index.html). Accessed 15 August 2009.
27.World Health Organization. WHO Department of Immunization, Vaccines and Biologicals. Vaccine preventable diseases: monitoring system (http://www.who.int/vaccines/globalsummary/immunization/countryprofileselect.cfm). Accessed 8 May 2008.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Type Description Title
PDF
Supplementary materials

Lessler supplementary material
Tables and figures.pdf

 PDF (1.7 MB)
1.7 MB